Platform-derived Nanotherapeutics

About Flashpoint Therapeutics

Flashpoint Therapeutics is a private, clinical-stage biotech leveraging a nanotechnology platform pioneered in Chad Mirkin's lab to create targeted, multi-component nanomedicines. Its platform, validated in vivo and with an IND-cleared candidate, demonstrates significant improvements in potency, delivery, and stability across various therapeutic modalities, including cancer immunotherapy. The company is advancing an internal pipeline while seeking strategic partnerships to develop best-in-class RNA and peptide therapeutics.

Therapeutic Areas